Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 PYXS | Healthcare | $1.58 | 359.90K | $188.98M | -1.22 | ― | Strong Buy |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| PYXS | Pyxis Oncology | 1.58 | -2.78 | -63.76% |
| Name | Price | % Change | |
|---|---|---|---|
| PYXS | $1.58 | -63.76% |
Pyxis Oncology ( ($PYXS) ) has provided an announcement. On November 13, 2026, the Company held a virtual special meeting, where 84,997,679 of its 119,583,637 outstanding shares were represented, establishing
Wedbush lowered the firm’s price target on Pyxis Oncology (PYXS) to $7 from $8 and keeps an Outperform rating on the shares after the company reported third quarter financials and
Stifel lowered the firm’s price target on Pyxis Oncology (PYXS) to $5 from $7 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate source
“The September monotherapy data reinforce our confidence in MICVO’s potential to serve a significant population of patients with previously treated recurrent/metastatic head and neck cancer,” said Tom Civik, Chief Executive
Pyxis Oncology (PYXS) announced that it closed its previously announced registered public offering on October 1, 2026. The Offering generated approximately $110.0 million in upfront gross proceeds, before deducting underwriting
Leerink, Guggenheim and Wells Fargo acted as joint book running managers for the offering. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
The major averages slipped for the second consecutive day despite the decline in oil prices as rising treasury yields remain top of mind for investors. Utilities was the best-performing area
Pyxis Oncology (PYXS) announced that it has commenced a registered public offering of (i) shares of its common stock, or in lieu of common stock to certain investors, pre-funded warrants
Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Pyxis Oncology, retaining the price target of $6.00. Sam Slutsky has given his Buy rating due to a combination
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Pyxis Oncology (PYXS) to $8 from $7 and keeps a Buy rating on the shares. The company’s updated data
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| PYXS | Mar 24, 2027TBA | $188.98M | $-0.22 | $25.00K | 0.30 | -1.22 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
